Skip to main content
Atrás
GLUE logo

Monte Rosa Therapeutics, Inc.

Calidad de datos: 100%
Sobreventa
GLUE
NASDAQ Healthcare Biotechnology
$14.72
▼ $0.31 (-2.06%)
Cap. Mercado: 958.61M
Rango del Día
$14.20 $14.92
Rango de 52 Semanas
$3.50 $25.77
Volumen
1,627,964
Promedio 50D / 200D
$19.78 / $11.73
Cierre Anterior
$15.03

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (627 pares)

Métrica Acción Mediana del Sector
P/E -24.8 0.3
P/B 4.1 2.9
ROE % -16.9 3.7
Net Margin % -31.2 3.8
Rev Growth 5Y % 10.0
D/E 0.2 0.2

Precio Objetivo de Analistas

Hold
$31.75 +115.7%
Low: $22.00 High: $37.00
EPS Futuro
-$1.52
Ingresos Est.
57 M

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 -$1.60
-$4.15 – -$0.19
170 M 1
FY2029 -$2.13
-$5.51 – -$0.25
120 M 1
FY2028 -$2.26
-$2.90 – -$1.47
38 M 5

Puntos Clave

Debt/Equity of 0.17 — conservative balance sheet
Negative free cash flow of -27.50M
PEG of 0.64 suggests growth is underpriced
Capital efficient — spends only 3.80% of revenue on capex

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)63.54%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-16.94%
ROIC-14.93%
Net Margin-31.23%
Op. Margin-43.83%

Seguridad

Debt / Equity
0.17
Current Ratio6.12
Interest Coverage0.00

Valoración

P/E Ratio
-24.82
P/B Ratio4.11
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 63.54% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 123.67M Net Income (TTM) -38.63M
ROE -16.94% ROA -8.61%
Gross Margin 93.24% Operating Margin -43.83%
Net Margin -31.23% Free Cash Flow (TTM) -27.50M
ROIC -14.93% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.17 Current Ratio 6.12
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -24.82 P/B Ratio 4.11
P/S Ratio 7.75 PEG Ratio 0.64
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 958.61M Enterprise Value 867.92M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 123.67M 75.62M 0.0 0.0 0.0
Net Income -38.63M -72.70M -135.35M -108.50M -73.96M
EPS (Diluted) -0.46 -0.98 -2.63 -2.30 -1.59
Gross Profit 115.32M 67.50M -6.22M 0.0 0.0
Operating Income -54.21M -81.11M -143.31M -112.38M -72.88M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 448.66M 438.73M 303.76M 342.39M 366.33M
Total Liabilities 215.60M 215.80M 124.51M 70.98M 18.81M
Shareholders' Equity 233.06M 222.94M 179.25M 271.41M 347.52M
Total Debt 39.19M 42.72M 46.04M 47.00M 0.0
Cash & Equivalents 129.88M 224.25M 128.10M 54.91M 346.07M
Current Assets 393.19M 377.44M 236.21M 275.89M 348.67M
Current Liabilities 64.21M 156.95M 46.59M 25.57M 16.64M